Scientists in the UK and Belgium have discovered new insights into how four different anti-amyloid drugs interact with amyloid beta protein, revealing why the drugs have had varying levels of success at treating Alzheimer’s disease.

Amyloid beta is one of the toxic proteins which builds up in clumps or ‘aggregates’ in the brains of people affected by Alzheimer’s. Several drugs targeting the protein have been tested in trials over recent years. These drugs are antibodies that bind to the amyloid beta and facilitate its clearance from the brain, but exactly how this occurs is not yet known.

In a new study, scientists compared four different anti-amyloid drugs: lecanemab, donanemab, aducanumab and gantenerumab, generating model protein aggregates in the lab, and also testing real aggregates taken from the brains of people who had died with Alzheimer’s.

The study was led by researchers from the UK Dementia Research Institute (UK DRI) at the University of Cambridge, the UK DRI at UCL, and the VIB-KU Leuven Center for Brain & Disease Research.  

The scientists used a new technique, pioneered at the UK DRI at Cambridge, to visualuse the size of protein aggregate each drug preferred to bind to, and how strongly each drug binds to aggregates. The highly sensitive technique, enabled the researchers to detect different sizes of soluble aggregate – from larger clumps of protein, down to very small aggregates. 

Lecanemab best for early treatment

In Alzheimer’s, a misfolded, sticky form of amyloid beta protein first groups together into small, soluble clumps called oligomers. Oligomers group together in turn to form fibrils, which then give rise to insoluble amyloid plaques. Scientists don’t yet know which form of amyloid is most damaging to cells, but there is evidence to suggest the smaller, soluble oligomers may be most toxic. 

In the new study, the researchers found that lecanemab performed best in binding to small oligomeric forms of the amyloid protein, suggesting a working mode for treating people in the earlier stages of Alzheimer’s and indicating that the drug is best used as early as possible in the disease progression.   

The team also found that lecanemab could bind at more sites per aggregate, allowing the drug to more effectively coat the toxic protein, making it more likely to be cleared. The team’s results for donanemab showed no binding to soluable aggregates, suggesting that it prefers to bind to larger insoluble aggregates known as ‘plaques’, which form in the spaces between nerve cells. 

The team says that further studies are needed to understand the impact of the drugs against insoluble aggregates. 

A way of testing future new Alzheimer’s drugs

Moving forward, the researchers hope their technique can be harnessed to test new and emerging therapies before they are rolled out into human trials, and offer key insight into how drugs work. 

Co-first author Emre Fertan, a PhD student at the UK Dementia Research Institute at the University of Cambridge, said: “In this study, we analysed how four different anti-amyloid drugs interact with the toxic amyloid beta protein that builds up in the brain in Alzheimer’s disease. We were interested in finding out more about the therapeutic effects of these drugs, by studying which type of aggregates they were targeting.

We found that, of the four drugs, lecanemab was the best at binding to small, soluble aggregates – the kind found in the brains of people with early-stage Alzheimer’s disease. From this, we can conclude that lecanemab is most effective when used at the earliest possible stage of disease.” 

Study co-leader Prof Sir David Klenerman, Group Leader at the UK Dementia Research Institute at the University of Cambridge, added: “Until now, we haven’t really understood exactly how anti-amyloid drugs work, or why some have been more successful than others in testing and clinical trials. With this study, we have been able to start to explain the differences we see when people are treated with these different Alzheimer’s drugs. 

In future, we hope there will be a wider application for this technique, in testing new and emerging drugs before they enter clinical trials. If we understand more about the therapeutic effect of these treatments at the pre-clinical stage, we may be able to optimise trial design and obtain better results.” 

Reece Armstrong, Editor, DDW